![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
A Subgroup Analysis of the Week 96 Efficacy and Safety Results Evaluating
Fostemsavir in Heavily Treatment-Experienced HIV-1 Infected Participants
in the Phase 3 BRIGHTE Study: Results From The Randomized Cohort
|
|
|
Reported by Jules Levin
10th IAS Conference on HIV Science (IAS 2019), 21-24 July 2019, Mexico City, Mexico
![0724191](../images/072519/072519-14/0724191.gif)
![0724192](../images/072519/072519-14/0724192.gif)
![0724193](../images/072519/072519-14/0724193.gif)
![0724194](../images/072519/072519-14/0724194.gif)
![0724195](../images/072519/072519-14/0724195.gif)
![0724196](../images/072519/072519-14/0724196.gif)
![0724197](../images/072519/072519-14/0724197.gif)
![0724198](../images/072519/072519-14/0724198.gif)
![0724199](../images/072519/072519-14/0724199.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|